NATCO PHARMA
Back to Income Statement
|
NATCO PHARMA Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹4,430 Cr | ₹3,999 Cr | ₹2,707 Cr | ₹1,945 Cr | ₹2,052 Cr |
What is the latest Revenue of NATCO PHARMA ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹4,430 Cr |
| Mar2024 | ₹3,999 Cr |
| Mar2023 | ₹2,707 Cr |
| Mar2022 | ₹1,945 Cr |
| Mar2021 | ₹2,052 Cr |
How is Revenue of NATCO PHARMA Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹4,430 Cr | 10.77 | |
| Mar2024 | ₹3,999 Cr | 47.72 | |
| Mar2023 | ₹2,707 Cr | 39.20 | |
| Mar2022 | ₹1,945 Cr | -5.23 | |
| Mar2021 | ₹2,052 Cr | - | |
Compare Revenue of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹16,938.4 Cr | -3.5% | 9.1% | -3.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹463,815.0 Cr | 0.5% | 6.2% | 17.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹192,678.0 Cr | 4.7% | 9% | 7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹161,323.0 Cr | -3.7% | 7.2% | 49.8% | Stock Analytics | |
| CIPLA | ₹114,585.0 Cr | -0.6% | 5% | -3.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,067.0 Cr | -1.9% | -4.6% | -2.8% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | -3.5% |
9.1% |
-3.3% |
| SENSEX | 0.8% |
1.8% |
-6.5% |
You may also like the below Video Courses